Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany

Qing Qiao,1 Mario JNM Ouwens,1 Susan Grandy,2 Kristina Johnsson,1 Karel Kostev3 1Global Medicines Development, AstraZeneca, Gothenburg, Sweden; 2Global Medicines Development, AstraZeneca, Gaithersburg, MD, USA; 3Epidemiology and Evidence-Based Medicine, Real-World Evidence Solutions, IMS Health, Fra...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qiao Q, Ouwens MJNM, Grandy S, Johnsson K, Kostev K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	type 2 diabetes GLP-1 receptor agonists adherence Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/9306438065de468c9331ee1729c05140
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9306438065de468c9331ee1729c05140
record_format	dspace
spelling	oai:doaj.org-article:9306438065de468c9331ee1729c051402021-12-02T02:47:37ZAdherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany1178-7007https://doaj.org/article/9306438065de468c9331ee1729c051402016-06-01T00:00:00Zhttps://www.dovepress.com/adherence-to-glp-1-receptor-agonist-therapy-administered-by-once-daily-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Qing Qiao,1 Mario JNM Ouwens,1 Susan Grandy,2 Kristina Johnsson,1 Karel Kostev3 1Global Medicines Development, AstraZeneca, Gothenburg, Sweden; 2Global Medicines Development, AstraZeneca, Gaithersburg, MD, USA; 3Epidemiology and Evidence-Based Medicine, Real-World Evidence Solutions, IMS Health, Frankfurt am Main, Germany Aim: This study aimed to compare 6-month adherence to therapy with exenatide once weekly (Bydureon®) vs liraglutide once daily (Victoza®) in patients with type 2 diabetes under primary care in Germany.Methods: A nationwide longitudinal prescription database (LRx), (between January 2011 and September 2014) was used to analyze adherence to therapy. The proportion of days covered (PDC) by prescription was used as a measure of adherence in the 6-month postindex period. Logistic regression analyses were performed to investigate the associations between glucagon-like peptide-1 receptor agonist therapy adjusting for age, sex, and cotherapy.Results: Therapy was initiated in 5,449 patients with exenatide once weekly (age: 59.7±11.8 years; 51.4% were male) and in 24,648 patients with liraglutide once daily (age: 59.4±11.4 years; 49.7% were male). The median PDC was 0.88 for exenatide once weekly and 0.77 for liraglutide once daily (P<0.05). Once-weekly exenatide was associated with significantly higher adherence. Odds ratio (95% confidence interval) for having a PDC of ≥0.80 was 1.78 (1.62–1.96) for exenatide once weekly compared with liraglutide once daily after adjusting for age, sex, and cotherapy.Conclusion: Adherence to treatment with exenatide once weekly was significantly increased compared to that with liraglutide once daily over 6 months in patients with type 2 diabetes. Keywords: type 2 diabetes, GLP-1 receptor agonists, adherenceQiao QOuwens MJNMGrandy SJohnsson KKostev KDove Medical Pressarticletype 2 diabetesGLP-1 receptor agonistsadherenceSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2016, Iss Issue 1, Pp 201-205 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	type 2 diabetes GLP-1 receptor agonists adherence Specialties of internal medicine RC581-951
spellingShingle	type 2 diabetes GLP-1 receptor agonists adherence Specialties of internal medicine RC581-951 Qiao Q Ouwens MJNM Grandy S Johnsson K Kostev K Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
description	Qing Qiao,1 Mario JNM Ouwens,1 Susan Grandy,2 Kristina Johnsson,1 Karel Kostev3 1Global Medicines Development, AstraZeneca, Gothenburg, Sweden; 2Global Medicines Development, AstraZeneca, Gaithersburg, MD, USA; 3Epidemiology and Evidence-Based Medicine, Real-World Evidence Solutions, IMS Health, Frankfurt am Main, Germany Aim: This study aimed to compare 6-month adherence to therapy with exenatide once weekly (Bydureon®) vs liraglutide once daily (Victoza®) in patients with type 2 diabetes under primary care in Germany.Methods: A nationwide longitudinal prescription database (LRx), (between January 2011 and September 2014) was used to analyze adherence to therapy. The proportion of days covered (PDC) by prescription was used as a measure of adherence in the 6-month postindex period. Logistic regression analyses were performed to investigate the associations between glucagon-like peptide-1 receptor agonist therapy adjusting for age, sex, and cotherapy.Results: Therapy was initiated in 5,449 patients with exenatide once weekly (age: 59.7±11.8 years; 51.4% were male) and in 24,648 patients with liraglutide once daily (age: 59.4±11.4 years; 49.7% were male). The median PDC was 0.88 for exenatide once weekly and 0.77 for liraglutide once daily (P<0.05). Once-weekly exenatide was associated with significantly higher adherence. Odds ratio (95% confidence interval) for having a PDC of ≥0.80 was 1.78 (1.62–1.96) for exenatide once weekly compared with liraglutide once daily after adjusting for age, sex, and cotherapy.Conclusion: Adherence to treatment with exenatide once weekly was significantly increased compared to that with liraglutide once daily over 6 months in patients with type 2 diabetes. Keywords: type 2 diabetes, GLP-1 receptor agonists, adherence
format	article
author	Qiao Q Ouwens MJNM Grandy S Johnsson K Kostev K
author_facet	Qiao Q Ouwens MJNM Grandy S Johnsson K Kostev K
author_sort	Qiao Q
title	Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
title_short	Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
title_full	Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
title_fullStr	Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
title_full_unstemmed	Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
title_sort	adherence to glp-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in germany
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/9306438065de468c9331ee1729c05140
work_keys_str_mv	AT qiaoq adherencetoglp1receptoragonisttherapyadministeredbyoncedailyoronceweeklyinjectioninpatientswithtype2diabetesingermany AT ouwensmjnm adherencetoglp1receptoragonisttherapyadministeredbyoncedailyoronceweeklyinjectioninpatientswithtype2diabetesingermany AT grandys adherencetoglp1receptoragonisttherapyadministeredbyoncedailyoronceweeklyinjectioninpatientswithtype2diabetesingermany AT johnssonk adherencetoglp1receptoragonisttherapyadministeredbyoncedailyoronceweeklyinjectioninpatientswithtype2diabetesingermany AT kostevk adherencetoglp1receptoragonisttherapyadministeredbyoncedailyoronceweeklyinjectioninpatientswithtype2diabetesingermany
_version_	1718402178822963200

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany

Ejemplares similares